Skip to content

Another negative result in the quest for a shorter TB treatment course

Sofosbuvir taken before or after liver transplant reduces hepatitis C recurrence

Michael Curry, of Beth Israel Deaconess Medical Center in Boston, speaking at The Liver Meeting 2013. Photo by Liz Highleyman, hivandhepatitis.com.

HIV may be becoming less fit as it adapts to the immune system

Hepatitis B treatment with entecavir or tenofovir lowers, but does not eliminate, liver cancer risk

Tung-Hung Su, of National Taiwan University Hospital, speaking at The Liver Meeting 2013. Photo by Liz Highleyman, hivandhepatitis.com

Sofosbuvir + ribavirin produces sustained response in 76% of genotype 1 HIV/HCV co-infected people

Mark Sulkowski, of Johns Hopkins Medical Center, speaking at The Liver Meeting 2013. Photo by Liz Highleyman, hivandhepatitis.com

Simeprevir + sofosbuvir produces high sustained response rates for hard-to-treat patients in COSMOS trial

Ira Jacobson, of Weill Cornell Medical College, speaking at The Liver Meeting 2013. Photo by Liz Highleyman, hivandhepatitis.com

BMS interferon-free combination cures over 90% of genotype 1 hepatitis C in 12 weeks

Gregory Everson of the University of Colorado speaking at The Liver Meeting 2013. Photo by Liz Highleyman, hivandhepatitis.com

Merck interferon-free combination shows high hepatitis C cure rate in early study

Need for expansion of hepatitis C screening among veterans, 'baby-boom' generation and pregnant women highlighted

James Galbraith, speaking at The Liver Meeting 2013. Photo by Liz Highleyman, hivandhepatitis.com